Table 3.
Effect of TCE on transplant outcomes for patients with 11/12 HLA match (N=166)*
| Clinical endpoint | TCE | N | Events | Hazard Ratio | 95% CI | P |
|---|---|---|---|---|---|---|
| OS | PR | 105 | 28 | |||
| NoPR | 61 | 22 | 1.38 | 0.79-2.42 | 0.26 | |
| EFS | PR | 105 | 36 | |||
| NoPR | 61 | 28 | 1.41 | 0.85-2.32 | 0.18 | |
| CIR | PR | 105 | 20 | |||
| NoPR | 61 | 10 | 0.75 | 0.34-1.66 | 0.48 | |
| NRM | PR | 105 | 16 | |||
| NoPR | 61 | 18 | 2.13 | 1.10-4.12 | 0.02 | |
| Acute GvHD II-IV | PR | 104 | 34 | |||
| NoPR | 61 | 32 | 1.97 | 1.22 -3.18 | 0.005 | |
| Acute GvHD III-IV | PR | 104 | 12 | |||
| NoPR | 61 | 10 | 1.42 | 0.62-3.23 | 0.40 | |
| Chronic GVHD | PR | 103 | 75 | |||
| NoPR | 61 | 44 | 1.02 | 0.69-1.50 | 0.93 |
*
All models are multivariable and adjusted for age (<58 vs. ≥58) and disease risk (high, intermediate, low/non-malignant). Patients with incomplete clinical data or with disease risk of other were excluded.